ArticleOpen forum infectious diseases2021
Preliminary, Real-world, Multicenter Experience With Omadacycline for
Open access · goldAbstract read
In one paragraph
Article in Open forum infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 48 citations in OpenAlex.
- Omadacycline Monotherapy in Nontuberculous Mycobacterial Pulmonary Disease Caused by Mycobacterium abscessus: Results From a Phase 2, Double-blind, Randomized, Placebo-controlled Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Trial
- Multicenter Real-World Outpatient Use of Intravenous Omadacycline.Infectious diseases and therapy · 2026Article
- Evaluation of the post-antibiotic effect againstMicrobiology spectrum · 2026Article
- Eravacycline forMicrobiology spectrum · 2026Article
- Eravacycline: From broad-spectrum coverage to novel clinical applications.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026Review
- Eravacycline pharmacokinetics/pharmacodynamics in the hollow fiber system model ofMicrobiology spectrum · 2026Article
- Coagulation dysfunction events associated with novel tetracycline-class drugs: a disproportionality and Bayesian analysis based on the FAERS database.Frontiers in antibiotics · 2026Article
- Mycobacteria susceptibility to epetraborole: how far can it go?The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2025Article
- Pharmacovigilance analysis of drug-induced hypofibrinogenemia using the FDA Adverse Event Reporting System.International journal of clinical pharmacy · 2025Article
- Drug susceptibility profiles ofJournal of medical microbiology · 2025Article
- New Perspectives on Antimicrobial Agents: Omadacycline for community-acquired pneumonia, skin and soft tissue infections, and nontuberculous mycobacteria (focus onAntimicrobial agents and chemotherapy · 2025Review
- Omadacycline drug susceptibility testing for non-tuberculous mycobacteria using oxyrase to overcome challenges with drug degradation.Tuberculosis (Edinburgh, Scotland) · 2024Article
- Article
- Pharmacotherapeutic Considerations in the Treatment of Nontuberculous Mycobacterial Infections: A Primer for Clinicians.Open forum infectious diseases · 2024Review
- Therapy ofMicroorganisms · 2024Review
- Omadacycline pharmacokinetics/pharmacodynamics and efficacy against multidrug-resistantAntimicrobial agents and chemotherapy · 2024Article
- Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomes.Antimicrobial agents and chemotherapy · 2023Article
- New Antimicrobials for Gram-Positive Sustained Infections: A Comprehensive Guide for Clinicians.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Comment on "Long-term Safety and Tolerability of Omadacycline for the Treatment ofOpen forum infectious diseases · 2023Article
- Long-term Safety and Tolerability of Omadacycline for the Treatment ofOpen forum infectious diseases · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 9 institutions in 1 country.
Taylor MorrisetteAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Sara AlosaimyAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Julie V PhilleyDivision of Pulmonary and Critical Care Medicine, University of Texas Health Science Center, University of Texas, Tyler, Texas, USA.
Carly WadleDivision of Pulmonary and Critical Care Medicine, University of Texas Health Science Center, University of Texas, Tyler, Texas, USA.
Catessa HowardDepartment of Pharmacy, West Virginia University Medicine, Morgantown, West Virginia, USA.
Andrew J WebbDepartment of Pharmacy, Mayo Clinic, Rochester, Minnesota, USA.
Michael P VeveDepartment of Clinical Pharmacy and Translational Science, College of Pharmacy, University of Tennessee Health Science Center, Knoxville, Tennessee, USA.
Melissa L BargerDepartment of Medicine, Ventura County Medical Center, Ventura, California, USA.
Jeannette BouchardCollege of Pharmacy, University of South Carolina, Columbia, South Carolina, USA.
Tristan W GoreCollege of Pharmacy, University of South Carolina, Columbia, South Carolina, USA.
Abdalhamid M LagnfAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Iman AnsariAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Carlos Mejia-ChewDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Keira A CohenDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Marlyand, USA.
Michael J RybakAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Eugene Applebaum College of Pharmacy and Health Sciences · USThe University of Texas Health Science Center at Tyler · USUniversity of South Carolina · USJohns Hopkins Medicine · USOregon Health & Science University · USUniversity of Tennessee Medical Center · USVentura County Medical Center · USWashington University in St. Louis · USWest Virginia University · US
Funding
A Pharmacologic Approach to Prevent Daptomycin Resistance in VRER01AI121400 · NIAID · WAYNE STATE UNIVERSITY · PI RYBAK, MICHAEL JOSEPH · 2016 to 2020
$1.9MImproved Tools for Nontuberculous Mycobacteria Lung DiseaseK08HL139994 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI COHEN, KEIRA ALEXIS · 2018 to 2022
$794kNHLBI NIH HHS K08 HL139994NIAID NIH HHS R01 AI121400
Abstract
Twelve patients were treated with omadacycline (OMC) as part of a multidrug regimen for
Indexed as
Mycobacterium abscessusomadacyclinerapidly growing nontuberculous mycobacteria
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.